Replimune Group (NASDAQ:REPL) Trading Down 4.2% – Time to Sell?

Shares of Replimune Group, Inc. (NASDAQ:REPL) traded down 4.2% during mid-day trading on Monday . The stock traded as low as $14.14 and last traded at $14.30. 134,294 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 1,050,196 shares. The stock had previously closed at $14.93.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on REPL shares. JPMorgan Chase & Co. increased their target price on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 24th. HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a report on Friday, November 22nd. Roth Mkm initiated coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target on the stock. BMO Capital Markets upped their price objective on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Friday, November 22nd. Finally, Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Replimune Group currently has an average rating of “Buy” and a consensus target price of $17.00.

Replimune Group Stock Performance

The firm has a fifty day simple moving average of $11.71 and a 200 day simple moving average of $9.86. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. The stock has a market cap of $961.26 million, a price-to-earnings ratio of -4.71 and a beta of 1.19.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. As a group, sell-side analysts expect that Replimune Group, Inc. will post -2.99 earnings per share for the current year.

Insider Buying and Selling

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the transaction, the insider now directly owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Several large investors have recently made changes to their positions in REPL. Nisa Investment Advisors LLC increased its holdings in shares of Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after buying an additional 4,946 shares in the last quarter. Point72 DIFC Ltd bought a new position in Replimune Group in the 2nd quarter valued at $57,000. Arizona State Retirement System bought a new stake in shares of Replimune Group during the second quarter worth $108,000. Quest Partners LLC grew its holdings in shares of Replimune Group by 30.4% during the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after purchasing an additional 3,150 shares during the last quarter. Finally, Erste Asset Management GmbH acquired a new stake in shares of Replimune Group in the third quarter valued at $133,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.